

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5206537

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ANDREW A. CALABRESE	09/24/2018
RECEIVING PARTY DATA	
Name:	ACIDOPHIL, LLC
Street Address:	10751 FALLS ROAD
Internal Address:	SUITE 300
City:	LUTHERVILLE
State/Country:	MARYLAND
Postal Code:	21093
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	15861368
PCT Number:	US2018012220
CORRESPONDENCE DATA	
Fax Number:	(336)607-7500
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3367477541
Email:	dcooke@kilpatricktownsend.com
Correspondent Name:	CYNTHIA B. ROTHSCHILD
Address Line 1:	KILPATRICK TOWNSEND & STOCKTON LLP
Address Line 2:	1001 WEST FOURTH STREET
Address Line 4:	WINSTON-SALEM, NORTH CAROLINA 27101
ATTORNEY DOCKET NUMBER:	098816-1071294
NAME OF SUBMITTER:	DEBBIE K. COOKE
SIGNATURE:	/Debbie K. Cooke/
DATE SIGNED:	10/25/2018
Total Attachments: 3	
source=AssignmentCallabresetoAcidophil-USandPCT - 1071294#page1.tif	
source=AssignmentCallabresetoAcidophil-USandPCT - 1071294#page2.tif	
source=AssignmentCallabresetoAcidophil-USandPCT - 1071294#page3.tif	

Attorney Docket No.	098816-1071294	098816-1071293
Client Ref.	ASP 012 US	ASP 012 PCT

ASSIGNMENT
(Patent Application)

I, ANDREW A. CALABRESE (the "Inventor,"), have invented certain inventions and improvements disclosed in the below-identified patent application entitled:

**"AZIRIDINE SPINOSYN DERIVATIVES AND
METHODS OF MAKING"**

and identified as U.S. Patent Application No. 15/861,368, filed on January 3, 2018, and PCT Patent Application No. PCT/US2018/012220, filed on January 3, 2018 with the U.S. Patent and Trademark Office.

For good and valuable consideration, the receipt and sufficiency of which I acknowledge, I, the Inventor:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Acidophil, LLC, a corporation of the State of Maryland having a principal place of business at 10751 Falls Road, Suite 300, Lutherville, MD 21093 ("the Assignee"), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application(s), implicitly or explicitly;
 - (b) the above-referenced patent application(s), the right to claim priority to the above-referenced patent application(s) in the United States and all foreign countries, and as provided by any bilateral or multilateral treaty or international agreement, including but not limited to, the International Convention of 1883 and later modifications thereof ("the Paris Convention"), the Patent Cooperation Treaty (PCT), the European Patent Convention, the Eurasian Patent Convention, the agreement(s) of the African Regional Intellectual Property Organization, the agreement(s) of the Organisation Africaine de la Propriete Intellectuelle, and the agreement(s) of the Cooperation Council for the Arab States of the Gulf, in all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination, or non-U.S. patent application, PCT applications, or applications for other rights based in whole or in part on the above-referenced patent application;

Patent Application

Attorney Docket No.	098816-10711294	098816-1071293
Client Ref.	ASP 012.US	ASP 012.PCT

- (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
 3. Authorize the Assignee to apply in all countries in my name or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventors' certificates for said inventions and improvements.
 4. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
 5. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon me, as well as my heirs, legal representatives, and assigns.
 6. Promise and affirm that I have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Patent Application

Attorney Docket No.	098816-10711294	098816-1071293
Client Ref.	ASP 012.US	ASP 012.PCT

Signed on the date indicated beside my signature.

SIGNATURE:

24th Sept 2018
Date


Andrew A. Calabrese


SIGNATURE WITNESSED BY:

Michael Lopez
Name of Witness (printed)


Signature of Witness

24th Sept. 2018
Date Witnessed

YooMin Ko
Name of Witness (printed)


Signature of Witness

24th Sept. 2018
Date Witnessed